focus -WSS

focus

author：focus 2025-09-30 19:25:57 - browse：2

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Do digital therapeutics have a future in medicine?

entertainment

WSS

Editas, Vertex strike deal on CRISPR

Medicare Advantage beneficiaries sue Humana over algorithm use

Virtual care provider acquires bankrupt Pear's prescription apps

Can sheer will power keep patients alive in their dying hours?

Why health care costs have stayed mostly flat since 2010

Virtual care provider acquires bankrupt Pear's prescription apps

knowledge

focus

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

What does generative AI mean for health care? We asked experts

Vertex non

At least 13 dead in Texas as scorching temps continue

SNAP should offer more nutrition education

The cancer drug shortage isn’t new — and neither are the solutions

FDA drug safety: Singulair case shows systemic surveillance flaws

In Memoriam: Notable people who died in 2023

FDA drug safety: Singulair case shows systemic surveillance flaws

Wikipedia

David Ricks of Eli Lilly: best biopharma CEO of 2023

Commercial surrogacy can be ethical, despite pope’s claims

The lessons of Aduhelm, an Alzheimer's drug that was not to be

SEC charges former device maker CEO with $41 million fraud

FDA drug safety: Singulair case shows systemic surveillance flaws

Biden administration opens offers in Medicare drug price negotiations

hotspot

knowledge

entertainment

Wikipedia